Immune checkpoint inhibitor-induced diabetes mellitus: A review of mechanisms, clinical features, and therapeutic approaches.
Since the FDA approval of ipilimumab in 2011, immune checkpoint inhibitors (ICIs) have reshaped the paradigm of cancer treatments. This has been pursued with the development and clinical investigation of combination immunotherapies with multiple ICIs. However, more than 20% of recipients of ICI monotherapy and a higher...